Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 19;11(1):14715.
doi: 10.1038/s41598-021-94219-z.

Dynamics of inhaled corticosteroid use are associated with asthma attacks

Affiliations

Dynamics of inhaled corticosteroid use are associated with asthma attacks

Joy Lee et al. Sci Rep. .

Abstract

Inhaled corticosteroids (ICS) suppress eosinophilic airway inflammation in asthma, but patients may not adhere to prescribed use. Mean adherence-averaging total doses taken over prescribed-fails to capture many aspects of adherence. Patients with difficult-to-treat asthma underwent electronic monitoring of ICS, with data collected over 50 days. These were used to calculate entropy (H) a measure of irregular inhaler use over this period, defined in terms of transitional probabilities between different levels of adherence, further partitioned into increasing (Hinc) or decreasing (Hdec) adherence. Mean adherence, time between actuations (Gapmax), and cumulative time- and dose-based variability (area-under-the-curve) were measured. Associations between adherence metrics and 6-month asthma status and attacks were assessed. Only H and Hdec were associated with poor baseline status and 6-month outcomes: H and Hdec correlated negatively with baseline quality of life (H:Spearman rS = - 0·330, p = 0·019, Hdec:rS = - 0·385, p = 0·006) and symptom control (H:rS = - 0·288, p = 0·041, Hdec: rS = - 0·351, p = 0·012). H was associated with subsequent asthma attacks requiring hospitalisation (Wilcoxon Z-statistic = - 2.34, p = 0·019), and Hdec with subsequent asthma attacks of other severities. Significant associations were maintained in multivariable analyses, except when adjusted for blood eosinophils. Entropy analysis may provide insight into adherence behavior, and guide assessment and improvement of adherence in uncontrolled asthma.

PubMed Disclaimer

Conflict of interest statement

MJA holds investigator-initiated grants for unrelated research from Pfizer and Boehringer-Ingelheim. He has undertaken an unrelated consultancy for and received assistance with conference attendance from Sanofi. He has also received a speaker’s fee from GSK. HKR or her institute has received fees for providing independent medical advice on advisory boards for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Sanofi/Genzyme, for providing independent medical education at symposia funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Novartis and Teva, and research grants from AstraZeneca, GlaxoSmithKline and Novartis, all unrelated to this research. MH has received grants-in-aid, speaker fees, and fees for serving on the advisory boards of GlaxoSmithKline, AstraZeneca, Novartis, Teva, Sanofi, and Seqirus, all unrelated to the current manuscript, all paid to his institutional employer Alfred Health. JL has received fees for providing unrelated independent medical advice for GlaxoSmithKline and has provided speaker fees for medical education purposes from Boehringer Ingelheim, GlaxoSmithKline and AstraZeneca. HR reports grants and personal fees from AstraZeneca, grants and personal fees from GlaxoSmithKline, personal fees from Merck, grants and personal fees from Novartis, personal fees from Teva, personal fees from Boehringer Ingelheim, personal fees from Sanofi Genzyme, outside the submitted work. CT is a NHMRC Career Development Fellow (Level 1). JL received support through an Australian Government Research Training Program Scholarship. Both funding sources had no role in study design, collection, analysis, interpretation of data, writing of the report of decision to submit this manuscript for publication. JH and JF have no competing interests to disclose.

Figures

Figure 1
Figure 1
Assessment protocol timeline, visits and clinical measures. EMD electronic monitoring device, ACT asthma control test, AQLQ asthma quality of life. (Microsoft Powerpoint, version 2101, https://office.live.com/start/powerpoint.aspx).
Figure 2
Figure 2
Calculation of entropy. Panel (a) shows a perfectly-adherent time series (green) in the background comprising 100% of prescribed puffs for 100% of the time, and an example patient time series (blue) overlaid atop the perfectly-adherent series, with instances of under- and over-adherence, both mapped to the state-based series. Panel (b) displays the corresponding transitional probability matrix, while panel (c) allows us to visualise the same matrix (and the “disorder”) in a 3-dimensional graph. The entropy of the transitional probability matrix is then calculated as i,j=0N-1Pi,j(-ln(Pi,j)). (Python Software Foundation, version 3·6 http://www.python.org).
Figure 3
Figure 3
Sample adherence time series from 4 different patients over the study period. All patients had ‘good adherence’ as defined by mean adherence PTmean (note not capped at 100% for the purpose of demonstrating variability), however with different increasing and decreasing entropy (Hinc and Hdec) measures, which better reflect the variability in patient inhaler adherence behaviour. Panel (a) demonstrates a patient who took their inhaled controller on average 84% of prescribed doses with calculated entropy 2.24 and increasing entropy 1.61. Panel (b) demonstrates a second patient who took their controller 90% of prescribed doses, with calculated entropy of 2.32 and increasing entropy of 0.92. Panel (c) demonstrates a third patient who took their controller 102.5% of prescribe doses, with calculated entropy of 1.85 and decreasing entropy of 0.95. Panel (d) demonstrates a fourth patient who took their controller 102.5% of prescribed doses, with calculated entropy of 1.86 and decreasing entropy of 0.59. (Python Software Foundation, version 3·6 http://www.python.org).
Figure 4
Figure 4
Consort diagram demonstrating flow of participants through the study. EMD electronic monitoring device. Due to EMD detachment. (Microsoft Powerpoint, version 2101, https://office.live.com/start/powerpoint.aspx).
Figure 5
Figure 5
Entropy metrics (over day 0–50) predict asthma outcomes (over days 0–180). Panel (a): Entropy (H) and attacks requiring hospitalisation. Panels (bd): Decreasing entropy (Hdec) and attacks requiring general practitioner (GP) visit, oral corticosteroids or hospitalisation respectively. The boxes depict the 25th, 50th, and 75th percentiles while the whiskers depict the minimum and maximum values in the data. The individual data points are also shown as dots. (R version 3·3 https://www.R-project.org/).

Similar articles

Cited by

References

    1. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J. Allergy Clin. Immunol. 1998;102:531–538. doi: 10.1016/S0091-6749(98)70268-4. - DOI - PubMed
    1. Demarche SF, et al. Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: A retrospective cohort study in a secondary care centre. BMJ Open. 2017;7:e018186. doi: 10.1136/bmjopen-2017-018186. - DOI - PMC - PubMed
    1. GINA. Diagnosis and management of difficult-to-treat and severe asthma in adolescent and adult patients. (2019). Available online at https://ginasthma.org/wp-content/uploads/2018/11/GINA-SA-FINAL-wms.pdf.
    1. Vrijens B, et al. What we mean when we talk about adherence in respiratory medicine. J. Allergy Clin. Immunol. Pract. 2016;4:802–812. doi: 10.1016/j.jaip.2016.05.019. - DOI - PubMed
    1. Kini V, Ho PM. Interventions to improve medication adherence. JAMA. 2018;320:2461. doi: 10.1001/jama.2018.19271. - DOI - PubMed

Substances